On this page
Osteoporosis
Also known as Low bone mineral density
This condition weakens bones over time, significantly increasing the risk of breaks, often from minor falls. It predominantly affects individuals over 50, with women being more frequently affected than men, and poses a considerable public health challenge in the UK.
Available at Jeen Health
Clinical tests that include this
Overview
Osteoporosis is a skeletal disorder where bones become less dense and more porous, losing strength and increasing their susceptibility to fractures [PMID:32505503]. This reduction in bone mass occurs without a corresponding genetic change affecting the bone's basic structure. The condition develops gradually, often without noticeable symptoms until a fracture occurs, commonly in the hip, spine, or wrist. It is a significant health concern in the UK, affecting approximately 3.5 million people.
Bone is a living tissue that is constantly being broken down and rebuilt in a process called bone remodelling. In osteoporosis, the balance shifts, with more bone being lost than replaced. This leads to weaker bones that can break more easily, even from minor stresses like a cough or a fall from standing height.
Symptoms & clinical features
Osteoporosis is often called a 'silent disease' because it typically does not cause symptoms in its early stages. The first indication that someone has osteoporosis is often a bone fracture following a minor injury that would not normally cause a break. Such fractures are known as fragility fractures.
Common sites for fragility fractures include the hip, spine (vertebrae), and wrist. Spinal fractures, even if not immediately obvious, can lead to a loss of height or a stooped posture (kyphosis) over time. Pain may also result from these fractures. Other less common symptoms might include back pain, which can be severe if a vertebral bone collapses.
Video: Genetics 101
Affected organs
Osteoporosis primarily affects the skeletal system, which comprises all the bones in the body. While all bones can be affected by the reduced density, the most common sites for fragility fractures include the hip, vertebrae (bones of the spine), and the radius (one of the forearm bones, near the wrist). These areas are particularly vulnerable due to their structure and weight-bearing function.
The impact on these bones can lead to chronic pain, mobility issues, and a reduced quality of life. Repeated spinal fractures, for instance, can lead to spinal deformity, which in turn can affect other bodily functions such as breathing and digestion, although this is less common.
Risks & severity
The severity of osteoporosis can vary, ranging from mild bone density loss (osteopenia) to severe osteoporosis with multiple fragility fractures. The risk of developing osteoporosis increases significantly with age; in the UK, roughly 1 in 2 women and 1 in 5 men over the age of 50 will experience a bone fracture mainly due to osteoporosis. Women are more susceptible, particularly after menopause, due to a sharp decline in oestrogen levels which play a crucial role in maintaining bone density [PMID:31613945].
Other risk factors include a family history of osteoporosis, certain medical conditions (e.g., rheumatoid arthritis, coeliac disease), long-term use of some medications (e.g., corticosteroids), low body weight, excessive alcohol consumption, smoking, and a lack of physical activity. A fracture due to osteoporosis can have a significant impact on an individual's independence and overall health, and severe cases can be life-threatening, particularly hip fractures in older adults.
Genetic causes
Osteoporosis is considered a complex or polygenic condition, meaning it does not typically result from a change in a single gene. Instead, it is influenced by a combination of many different genes, each contributing a small effect, alongside environmental and lifestyle factors. Research has identified several genes that are associated with an increased risk of developing osteoporosis.
These include *ESR1*, which encodes for oestrogen receptor 1, a key player in bone metabolism and density. Variants in *LRP5* (LDL receptor related protein 5) are also linked, as this gene is important in the Wnt signalling pathway which regulates bone formation. Genes like *SOST* (sclerostin) and *WNT16* (Wnt family member 16) are also involved in this pathway and have been associated with bone mineral density. Variations within these genes can influence how effectively bones are formed and maintained, thereby affecting an individual's susceptibility to osteoporosis [PMID:33671754].
Inheritance pattern
Osteoporosis has a complex inheritance pattern, meaning it is not inherited in a simple dominant or recessive fashion. Instead, an individual's risk is influenced by a combination of multiple genetic variations from both parents, as well as environmental factors such as diet, exercise, and lifestyle choices. This means that if osteoporosis runs in your family, you may have an increased genetic predisposition, but it does not guarantee you will develop the condition.
While specific genetic factors can contribute to susceptibility, having a genetic variant associated with osteoporosis does not mean the condition is inevitable. Likewise, not having such variants does not guarantee full protection against it. Family history is an important risk factor, where having a parent who fractured a hip increases one's own risk.
Diagnosis & testing
Diagnosing osteoporosis typically involves a combination of assessing an individual's medical history, performing a physical examination, and using a specialised X-ray scan called a DXA (Dual-energy X-ray Absorptiometry) scan. A DXA scan measures bone mineral density (BMD), usually at the hip and spine, and compares it to the average BMD of healthy young adults and age-matched individuals to determine if bone density is low.
In the UK, suspected cases of osteoporosis can be referred for DXA scans through general practitioners or specialist clinics. The NHS Genomic Medicine Service does not typically offer specific genetic testing for general osteoporosis risk as part of routine care, given its complex, polygenic nature. However, where a specific genetic cause for severe, early-onset, or unusual forms of osteoporosis (e.g., monogenic forms) is suspected, a clinical genetics team may consider further investigation for specific genes under appropriate NHS R-codes.
Management & lifestyle
Management of osteoporosis in the UK focuses on preventing fractures, maintaining bone density, and minimising the impact of the condition. Treatment plans are individualised and often involve a combination of medication, lifestyle adjustments, and regular monitoring. Medications commonly prescribed include bisphosphonates, which slow down bone loss, and sometimes other agents that help build bone or mimic the action of natural hormones.
Lifestyle changes are crucial and generally involve ensuring adequate intake of calcium and vitamin D, engaging in regular weight-bearing and muscle-strengthening exercises, and avoiding smoking and excessive alcohol consumption. Physiotherapy can help improve balance and reduce the risk of falls, a major cause of fractures. Patients in the UK can access care through their GP, who can refer to endocrinologists, rheumatologists, or orthopaedic specialists, and bone health clinics for comprehensive management. Genetic counsellors are not typically involved in the management of common osteoporosis but may play a role in rare, genetically-driven bone fragility disorders.
UK care pathway
In the UK, individuals concerned about osteoporosis or potential bone fragility often begin by consulting their General Practitioner (GP). The GP can assess risk factors and arrange initial investigations, which may include blood tests and a referral for a DXA scan to measure bone mineral density. Depending on the findings, patients may be referred to specialists such as rheumatologists or endocrinologists, who specialise in bone health and metabolic conditions, for further assessment and management.
While osteoporosis is primarily managed through these clinical pathways, complex cases or very early-onset instances where a specific genetic cause might be suspected could lead to a referral to a Clinical Genetics service. Within clinical genetics, if genetic testing is considered appropriate for very rare monogenic forms of bone fragility, it would be sought through the NHS Genomic Medicine Service using relevant R-codes for specific genes or panels (e.g., R151 for causes of early-onset osteoporosis), following assessment and counselling by a genetic counsellor.
Frequently asked questions
Can I prevent osteoporosis?
While you can't prevent all cases, you can significantly reduce your risk through lifestyle choices. These include a calcium and vitamin D-rich diet, regular weight-bearing exercise, avoiding smoking, and limiting alcohol intake. Early intervention is key, particularly for those with strong family histories.
What is a DXA scan?
A DXA (Dual-energy X-ray Absorptiometry) scan is a quick, low-radiation X-ray that measures the density of your bones. It's the standard test for diagnosing osteoporosis and assessing your risk of fractures, typically focusing on the hip and spine.
Is osteoporosis always inherited?
Osteoporosis is not simply inherited like some single-gene conditions. It's considered a complex condition where many genes contribute small effects, along with significant environmental and lifestyle factors. Having a family history increases your risk, but it doesn't mean you will definitely develop it.
What kind of exercise is best for bones?
Weight-bearing exercises, where your bones support your body weight, are beneficial. Examples include walking, jogging, dancing, and climbing stairs. Muscle-strengthening exercises, such as lifting weights or using resistance bands, also help improve bone density and balance.
Who is most at risk of developing osteoporosis?
Older adults, particularly post-menopausal women, are at the highest risk. Other significant risk factors include a family history of the condition, certain medical conditions or medications, low body weight, smoking, and heavy alcohol consumption.
References
- Yu B, Wang CY. Osteoporosis and periodontal diseases - An update on their association and mechanistic links. Periodontology 2000. 2022. PMID: 35244945
- Tański W, Kosiorowska J, Szymańska-Chabowska A. Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment. European review for medical and pharmacological sciences. 2021. PMID: 34002830
- Song S, Guo Y, Yang Y. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacology & therapeutics. 2022. PMID: 35283172
- Kumar L, Arora MK, Marwah S. Biologic Antiresorptive: Denosumab. Indian journal of orthopaedics. 2023. PMID: 38107799
- Wu B, Fu Z, Wang X. A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment. Frontiers in endocrinology. 2022. PMID: 36589835
- Cohen A. Premenopausal Osteoporosis. Endocrinology and metabolism clinics of North America. 2017. PMID: 28131128
- Keen MU, Barnett MJ, Anastasopoulou C. Osteoporosis in Females. 2026. PMID: 32644582
- Porter JL, Varacallo MA. Osteoporosis. 2026. PMID: 28722930